XML 84 R60.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies - Additional Information (Details) - USD ($)
1 Months Ended 12 Months Ended
Feb. 10, 2016
Jul. 31, 2010
Dec. 31, 2017
Dec. 31, 2015
Commitments And Contingencies [Line Items]        
Milestone payment   $ 4,700,000.0    
Common stock, shares issued (in shares)   105,000    
License agreement, termination period 60 days      
University of Zurich        
Commitments And Contingencies [Line Items]        
Percentage of royalty on net product sales (as a percent)     4.00%  
Percentage requiring reduction in the amount of royalties owned (as a percent)     10.00%  
Minimum percentage of royalty on net product sales (as a percent)     2.00%  
University of Zurich | Clinical Development Milestone        
Commitments And Contingencies [Line Items]        
Amount payable upon achievement of first milestone     $ 750,000  
Merck KGaA        
Commitments And Contingencies [Line Items]        
Amount payable upon achievement of first milestone     $ 4,000,000  
Percentage of royalty on net product sales (as a percent)     1.50%  
License agreement, amount payable upon start of the first phase 3 clinical trial for licensed product     $ 2,000,000  
License agreement, amount payable upon submission of the first biologics license application (BLA) for a licensed product     2,000,000  
License agreement, amount payable upon the approval of the first BLA in certain countries for a licensed product     2,000,000  
License agreement, amount payable upon each of the second and third approvals of a BLA in certain additional countries for the same licensed product     1,000,000  
License agreement, amount payable upon the approval of the second BLA in certain countries for a licensed product     2,000,000  
License agreement, amount payable upon each of the second and third approvals of the second BLA in certain additional countries for the same licensed product     1,000,000  
License agreement, royalty payable on net product sales, maximum amount     $ 150,000,000  
Period of expiration of first commercial sale of a licensed product     10 years  
Maximum period of duration of non-payment of royalty of a licensed product     15 years  
Clinical Development        
Commitments And Contingencies [Line Items]        
Milestone payment upon achievement of clinical milestone       $ 350,000